Search | IOVS | ARVO Journals

Showing 1 – 20 of 36

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Treatment with soluble Fas ligand prevents disease progression in the DBA/2J chronic mouse model of glaucoma

Sarah Dickman; Anitha Krishnan; Bhupender Verma; Ann Marshak-Rothstein; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):946.

ARVO Annual Meeting Abstract June 2024

The NLRP3 inflammasome mediates neurodegeneration in an ischemia-reperfusion injury model of acute angle-closure glaucoma

Andrew R. Griswold; Sarah B. Dickman; Victoria McGilligan; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):699.

ARVO Annual Meeting Abstract June 2024

Microglia activation and its modulation following RGC transplantation.

Volha Malechka; Josy Augustine; Meredith S Gregory-Ksander; Petr Y Baranov

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2781.

ARVO Annual Meeting Abstract June 2024

Complement factor B as a strategic target for inhibiting neuroinflammation and protecting retinal ganglion cells in a microbead-induced mouse model of glaucoma

Cindy Hoppe; Nasrin Refaian; Amarachi Nwogu; Maleeka Shrestha; Yinjie Guo; Kip Connor; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3813.

ARVO Annual Meeting Abstract June 2023

Non-human primate laser-induced NAION model for assessing neuro-rejuvenating gene therapies

Madhura Shah; Drenushe Krasniqi; Meredith S Gregory-Ksander; Sharon Rosenzweig-Lipson; Kasia Broniowska; Michel Wathier; Joan Mannick; Jennifer Cermak; Margarete Karg; Shintaro Shirahama; Nasrin Refaian; Yuancheng Lu; Bruce Ksander; Matthew Lawrence; David Sinclair; Joseph F. Rizzo

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5223.

ARVO Annual Meeting Abstract June 2023

Epigenetic reprogramming to rejuvenate retinal ganglion cells and sustainably reverse glaucoma-induced vision loss

Yuancheng Ryan Lu; Margarete Karg; Emma M. Hoffmann; James C. Cameron; May Moorefield; Maleeka Shrestha; Yinjie Guo; Joan Mannick; Jennifer Cermak; Michel Wathier; Meredith S Gregory-Ksander; David Sinclair; Bruce Ksander

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2841.

ARVO Annual Meeting Abstract June 2023

Epigenetic reprogramming- A novel gene therapy that restores vision loss in a nonhuman primate model of NAION

Bruce Ksander; Madhura Shah; Drenushe Krasniqi; Meredith S Gregory-Ksander; Sharon Rosenzweig-Lipson; Kasia Broniowska; Michel Wathier; Joan Mannick; Jennifer Cermak; Margarete Karg; Shintaro Shirahama; Nasrin Refaian; Yuancheng Lu; Matthew Lawrence; Joseph F. Rizzo; David Sinclair

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):474.

ARVO Annual Meeting Abstract June 2023

The alternative complement pathway triggers neuroinflammation, glial activation, and retinal ganglion cell death in a microbead induced mouse model of glaucoma

Cindy Hoppe; Nasrin Refaian; Drenushe Krasniqi; Amarachi Nwogu; Yinjie Guo; Maleeka Shrestha; Kip M Connor; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1574.

ARVO Annual Meeting Abstract June 2023

Local antigen-presenting cells and restimulation of T cells during uveitis

Shintaro Shirahama; Yoko Okunuki; May Yue Lee; Meredith S Gregory-Ksander; Kip M Connor; Bruce Ksander

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2456.

ARVO Annual Meeting Abstract June 2023

Post injury treatment with intravitreal AAV2-soluble Fas ligand restores retinal microglia homeostasis and rescues retinal ganglion cell function in a mouse model of glaucoma

Meredith S Gregory-Ksander; Anitha Krishnan; Maleeka Shrestha; Khoa Nguyen; Ann Marshak-Rotstein

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2583.

ARVO Annual Meeting Abstract June 2022

Uncoupling caspase 8-mediated-apotosis from caspase 8-mediated-inflammation in glaucoma

Yinjie Guo; Maleeka Shrestha; Ann Marshak-Rothstein; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1610 – A0433.

ARVO Annual Meeting Abstract June 2022

Targeting the alternative complement pathway as a neuroprotective therapy in glaucoma and optic nerve injury

Cindy Hoppe; Yinjie Guo; Maleeka Shrestha; Bhupender Verma; Kip M Connor; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1609 – A0432.

ARVO Annual Meeting Abstract June 2022

MHC class II positive retinal microglia exacerbate uveitis by activating infiltrating T cells

Shintaro Shirahama; May Yue Lee; Yoko Okunuki; Kip M Connor; Meredith S Gregory-Ksander; Bruce Ksander

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2684.

ARVO Annual Meeting Abstract June 2021

Depletion of optic nerve microglia does not improve visual function in experimental glaucoma

Zizhu Tan; Yinjie Guo; Maleeka Shrestha; Meredith S Gregory-Ksander; Tatjana C Jakobs

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2383.

ARVO Annual Meeting Abstract June 2021

Caspase-8-mediated inflammation but not apoptosis drives the development of glaucoma

Yinjie Guo; Maleeka Shrestha; Ann Marshak-Rothstein; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2350.

ARVO Annual Meeting Abstract June 2020

Reversal of aging-induced and glaucoma-induced vision loss by in vivo epigenetic reprogramming

Bruce Ksander; Yuancheng Lu; Anitha Krishnan; Benedikt Brommer; Xiao Tian; Margarita Meer; Daniel Vera; Chen Wang; Qiurui Zeng; Doudou Yu; Steve Horvath; Meredith S Gregory-Ksander; Zhigang He; David Sinclair

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2364.

ARVO Annual Meeting Abstract June 2020

InflaMab: A novel NLRP3 Inflammasome inhibitor provides neuroprotection in a mouse model of glaucoma

Melody Chemaly; Anitha Krishnan; Anthony J Bjourson; Aaron Peace; Meredith S Gregory-Ksander; Victoria McGilligan

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2365.

ARVO Annual Meeting Abstract June 2020

Intravitreal administration of AAV2.soluble Fas ligand gene therapy following glaucoma injury restores retinal ganglion cell function and stops disease progression

Meredith S Gregory-Ksander; Maleeka Shrestha; Khoa Nguyen; Ann Marshak-Rothstein; Anitha Krishnan

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2366.

ARVO Annual Meeting Abstract July 2019

Pharmacologic inhibition of the NLRP3 inflammasome - a novel neuroprotective therapy for glaucoma

Anitha Krishnan; Malvika Dua; Claire H Mitchell; Wennan Lu; Meredith S Gregory-Ksander

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2256.

ARVO Annual Meeting Abstract July 2019

Fas signaling triggers glial-mediated neuroinflammation in glaucoma

Meredith S Gregory-Ksander; Wennan Lu; Claire H Mitchell; Andrew Kocab; David N Zacks; Anitha Krishnan

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2257.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Treatment with soluble Fas ligand prevents disease progression in the DBA/2J chronic mouse model of glaucoma

The NLRP3 inflammasome mediates neurodegeneration in an ischemia-reperfusion injury model of acute angle-closure glaucoma

Microglia activation and its modulation following RGC transplantation.

Complement factor B as a strategic target for inhibiting neuroinflammation and protecting retinal ganglion cells in a microbead-induced mouse model of glaucoma

Non-human primate laser-induced NAION model for assessing neuro-rejuvenating gene therapies

Epigenetic reprogramming to rejuvenate retinal ganglion cells and sustainably reverse glaucoma-induced vision loss

Epigenetic reprogramming- A novel gene therapy that restores vision loss in a nonhuman primate model of NAION

The alternative complement pathway triggers neuroinflammation, glial activation, and retinal ganglion cell death in a microbead induced mouse model of glaucoma

Local antigen-presenting cells and restimulation of T cells during uveitis

Post injury treatment with intravitreal AAV2-soluble Fas ligand restores retinal microglia homeostasis and rescues retinal ganglion cell function in a mouse model of glaucoma

Uncoupling caspase 8-mediated-apotosis from caspase 8-mediated-inflammation in glaucoma

Targeting the alternative complement pathway as a neuroprotective therapy in glaucoma and optic nerve injury

MHC class II positive retinal microglia exacerbate uveitis by activating infiltrating T cells

Depletion of optic nerve microglia does not improve visual function in experimental glaucoma

Caspase-8-mediated inflammation but not apoptosis drives the development of glaucoma

Reversal of aging-induced and glaucoma-induced vision loss by in vivo epigenetic reprogramming

InflaMab: A novel NLRP3 Inflammasome inhibitor provides neuroprotection in a mouse model of glaucoma

Intravitreal administration of AAV2.soluble Fas ligand gene therapy following glaucoma injury restores retinal ganglion cell function and stops disease progression

Pharmacologic inhibition of the NLRP3 inflammasome - a novel neuroprotective therapy for glaucoma

Fas signaling triggers glial-mediated neuroinflammation in glaucoma

To View More...

You must be signed into an individual account to use this feature.